Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs BioCryst Pharmaceuticals, Inc.

Cost Efficiency: Teva vs. BioCryst Over a Decade

__timestampBioCryst Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20141220009216000000
Thursday, January 1, 201518960008296000000
Friday, January 1, 2016269900010044000000
Sunday, January 1, 2017170200011560000000
Monday, January 1, 201847100010558000000
Tuesday, January 1, 201941010009351000000
Wednesday, January 1, 202016760008933000000
Friday, January 1, 202172640008284000000
Saturday, January 1, 202265940007952000000
Sunday, January 1, 202346610008200000000
Monday, January 1, 20248480000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Pharmaceutical Giants: Cost Efficiency Over Time

In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis compares the cost of revenue efficiency between Teva Pharmaceutical Industries Limited and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Teva, a global leader, consistently reported a cost of revenue exceeding $8 billion annually, peaking in 2017 at approximately $11.56 billion. In contrast, BioCryst, a smaller player, showed a more volatile trend, with costs ranging from $122,000 in 2014 to a high of $7.26 million in 2021. Despite the vast difference in scale, BioCryst's cost efficiency improved significantly, with a 3,700% increase from 2014 to 2021. Meanwhile, Teva's costs decreased by about 31% from their peak. This data highlights the contrasting strategies and market positions of these two companies, offering insights into their operational efficiencies and market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025